X4 Pharmaceuticals, Inc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
XFOR$3.25-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss F-
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Product revenue, net | $2,557 | $— | $— |
| Costs and operating expenses: | |||
| Cost of revenue | 797 | — | — |
| Research and development | 81,643 | 72,017 | 61,058 |
| Selling, general and administrative | 61,518 | 35,505 | 27,020 |
| Gain on sale of non-financial assets | (105,000) | — | (509) |
| Total operating expenses | 38,958 | 107,522 | 87,569 |
| Loss from operations | (36,401) | (107,522) | (87,569) |
| Other (expense) income, net: | |||
| Interest income | 5,769 | 4,582 | 219 |
| Interest expense | (8,768) | (5,777) | (3,993) |
| Change in fair value of warrant and derivative liabilities | 1,928 | 7,074 | 1,701 |
| Other income (expense), net | 332 | 554 | (4,197) |
| Total other (expense) income, net | (739) | 6,433 | (6,270) |
| Loss before provision for income taxes | (37,140) | (101,089) | (93,839) |
| Provision for income taxes | 310 | 78 | 28 |
| Net loss | (37,450) | (101,167) | (93,867) |
| Deemed dividend on Class B Warrant price reset | — | — | (2,546) |
| Net loss attributable to common stockholders | $(37,450) | $(101,167) | $(96,413) |
| Net loss per share attributable to common stockholders—basic and diluted | $(0.19) | $(0.57) | $(1.52) |
| Weighted average shares of common stock outstanding—basic and diluted | 201,062,211 | 177,812,480 | 63,525,845 |
| Other comprehensive loss, net of tax | |||
| Net loss | $(37,450) | $(101,167) | (93,867) |
| Change in unrealized losses on marketable securities | (3) | — | — |
| Total comprehensive loss | $(37,453) | $(101,167) | $(93,867) |
| The accompanying notes are an integral part of these consolidated financial statements. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.